Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

News

$ZyVersa Therapeutics (ZVSA.US)$ ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
1 MINUTE AGO, 7:55 AM EST
VIA GLOBENEWSWIRE
Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.
Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.
The pathomechanism underlying cardiac dysfunction following a stroke includes a surge of catecholamines, such as epinephrine, which induces inflammasome activation triggering a systemic inflammatory response.
The published data showed that following a stroke, Inflammasome ASC Inhibitor IC 100 blocked AIM2 inflammasome activation and cell death (pyroptosis) in the heart and improved cardiac function.
Data from this article support ZyVersa's development of Inflammasome ASC Inhibitor IC 100 for obesity and its associated cardiovascular comorbidities.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
3
+0
4
Translate
Report
1718 Views
Comment
Sign in to post a comment
3576Followers
23Following
53KVisitors
Follow